A MULTICENTER, DOUBLEBLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY ASSESSING THE

一项多中心、双盲、随机、安慰剂对照研究评估

• 批准号: 7731323
• 负责人: STEVEN K. GRINSPOON
• 金额: $ 0.67万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7731323
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Funding; Goals; Grant; HIV; High Density Lipoprotein Cholesterol; Institution; Lipodystrophy; Obesity; Pharmaceutical Preparations; Research; Research Personnel; Resources; Somatotropin-Releasing Hormone; Source; TH9507; Triglycerides; United States National Institutes of Health; Visceral; randomized placebo controlled trial; Computer Retrieval of Information on Scientific Projects Database; Funding; Goals; Grant; HIV; High Density Lipoprotein Cholesterol; Institution; Lipodystrophy; Obesity; Pharmaceutical Preparations; Research; Research Personnel; Resources; Somatotropin-Releasing Hormone; Source; TH9507; Triglycerides; United States National Institutes of Health; Visceral; randomized placebo controlled trial

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary goal of this study is to determine the efficacy of the medication TH9507, a growth hormone releasing factor, in reducing excess visceral adiposity associated with HIV lipodystrophy. Secondary objectives include improvements in total cholesterol/HDL ratio and triglycerides and changes in IGF-I.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项研究的主要目的是确定药物Th9507（一种生长激素释放因子）的疗效，以降低与HIV脂肪营养不良相关的过量内脏肥胖。次要目标包括改善总胆固醇/HDL比和甘油三酸酯以及IGF-I的变化。